Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis
Launched by UNIVERSITY OF SAO PAULO GENERAL HOSPITAL · May 21, 2010
Trial Information
Current as of September 20, 2025
Completed
Keywords
ClinConnect Summary
Chronic autoimmune thyroiditis (CAT) is the most common cause of hypothyroidism in iodine-replete areas. An autoimmune dysfunction causes humoral and cellular responses that lead progressively to thyroiditis. There is no effective therapy available that can change the natural history of CAT, which presents a high incidence of hypothyroidism and requires continuous treatment with levothyroxine (LT4).
Laser light can be valuable since the local and systemic actions of low-level laser therapy (LLLT) have been shown to be effective in treating autoimmune diseases, such as rheumatoid arthritis ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients previously diagnosed with hypothyroidism induced by chronic autoimmune thyroiditis (CAT). The presence of hypothyroidism, laboratory measurements and ultrasonography criteria were applied to diagnose CAT.
- • Significantly elevated concentrations of thyroid peroxidase (TPOAb) and/or thyroglobulin (TgAb) autoantibodies
- • Ultrasonography results consistent with CAT
- • Patients undergoing LT4 treatment
- • Normal (or almost normal) levels of triiodothyronine (T3), thyroxine (T4), free T4 and thyrotropin (TSH)
- Exclusion Criteria:
- • Use of immunosuppressants, immunostimulants, or other drugs that could interfere with the production, metabolism and transport of thyroid hormones
- • CAT with normal thyroid function
- • CAT with subclinical hypothyroidism
- • Thyroid nodules
- • Hypothyroidism stemming from post-partum thyroiditis (up to 18 months after gestation)
- • History of Graves' disease
- • Thyrotropin receptor antibody (TRAb) detectable
- • Prior treatment with radioiodine
- • Tracheal stenosis
- • Pregnancy
- • History of ionizing irradiation and/or neoplasia in the cervical area
- • Previous surgical intervention in the thyroid
- • Thyroid hypoplasia
- • Ectopic thyroid
- • Serious illness (cancer, ischemic coronary artery disease, stroke, kidney or liver failure, etc.)
About University Of Sao Paulo General Hospital
The University of São Paulo General Hospital (Hospital das Clínicas da Universidade de São Paulo) is a leading clinical research institution in Brazil, renowned for its commitment to advancing medical knowledge and patient care. As an academic hospital affiliated with one of the largest and most prestigious universities in Latin America, it integrates clinical practice, education, and research. The hospital conducts a wide array of clinical trials across various medical disciplines, aiming to develop innovative therapies and improve healthcare outcomes. With a multidisciplinary team of healthcare professionals and access to cutting-edge facilities, the University of São Paulo General Hospital is dedicated to fostering scientific advancements and addressing critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
São Paulo, Brazil
Patients applied
Trial Officials
Danilo B Höfling, Dr.
Principal Investigator
University of São Paulo General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials